WO2007127212A3 - Anti-viral agents that activate rnase l - Google Patents
Anti-viral agents that activate rnase l Download PDFInfo
- Publication number
- WO2007127212A3 WO2007127212A3 PCT/US2007/009959 US2007009959W WO2007127212A3 WO 2007127212 A3 WO2007127212 A3 WO 2007127212A3 US 2007009959 W US2007009959 W US 2007009959W WO 2007127212 A3 WO2007127212 A3 WO 2007127212A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viral agents
- activate rnase
- rnase
- activate
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002650028A CA2650028A1 (en) | 2006-04-25 | 2007-04-25 | Anti-viral agents that activate rnase l |
AU2007243403A AU2007243403A1 (en) | 2006-04-25 | 2007-04-25 | Anti-viral agents that activate RNase L |
JP2009507765A JP2009536622A (en) | 2006-04-25 | 2007-04-25 | Antiviral agent that activates RNase L |
MX2008013668A MX2008013668A (en) | 2006-04-25 | 2007-04-25 | Anti-viral agents that activate rnase l. |
EP07755981A EP2016062A2 (en) | 2006-04-25 | 2007-04-25 | Anti-viral agents that activate rnase l |
IL194890A IL194890A0 (en) | 2006-04-25 | 2008-10-23 | ANTI-VIRAL AGENTS THAT ACTIVATE RNase L |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79506906P | 2006-04-25 | 2006-04-25 | |
US60/795,069 | 2006-04-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007127212A2 WO2007127212A2 (en) | 2007-11-08 |
WO2007127212A3 true WO2007127212A3 (en) | 2008-03-27 |
Family
ID=38374152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/009959 WO2007127212A2 (en) | 2006-04-25 | 2007-04-25 | Anti-viral agents that activate rnase l |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2016062A2 (en) |
JP (1) | JP2009536622A (en) |
KR (1) | KR20090007609A (en) |
CN (1) | CN101460471A (en) |
AU (1) | AU2007243403A1 (en) |
CA (1) | CA2650028A1 (en) |
IL (1) | IL194890A0 (en) |
MX (1) | MX2008013668A (en) |
RU (1) | RU2008146422A (en) |
WO (1) | WO2007127212A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009123588A1 (en) * | 2008-04-01 | 2009-10-08 | The Cleveland Clinic Foundation | Amides of 3, 5-substituted-is0xaz0le-4-carb0xylic acids for the treatment of viral infections, cancer and restenosis |
ES2660892T3 (en) * | 2009-03-23 | 2018-03-26 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for pain management |
EP2739629B1 (en) | 2011-08-05 | 2016-10-05 | Biota Scientific Management Pty Ltd | Compounds for treating respiratory syncytial virus infections |
RU2487708C1 (en) * | 2012-03-12 | 2013-07-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) | Method of treating parvoviral infection b19 in infants |
TWI472518B (en) * | 2014-01-02 | 2015-02-11 | Univ China Medical | Use of derivative of aniline in anti-virus application |
AU2017354372A1 (en) * | 2016-11-04 | 2019-06-20 | Carna Biosciences, Inc. | Furanone derivates and methods of use thereof |
CN109745311B (en) * | 2019-02-22 | 2021-12-17 | 北京大学深圳研究生院 | Application of RNase L enzyme inhibitor |
CN112107679A (en) * | 2020-09-28 | 2020-12-22 | 武汉愔紫生物科技有限公司 | Application of macromolecular protein in anti-RNA virus disinfectant |
CN112088903A (en) * | 2020-09-28 | 2020-12-18 | 武汉愔紫生物科技有限公司 | Application of macromolecular protein in antibacterial and antiviral disinfectant |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047760A2 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Novel chemical compounds |
US20050038051A1 (en) * | 2003-06-09 | 2005-02-17 | Jodi Nunnari | Novel molecules for regulating cell death |
US20050042213A1 (en) * | 2003-08-14 | 2005-02-24 | Insight Biopharmaceuticals Ltd. | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
WO2005051318A2 (en) * | 2003-11-24 | 2005-06-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
WO2005082363A1 (en) * | 2004-02-20 | 2005-09-09 | Board Of Regents, The University Of Texas System | Thiazolone compounds for treatment of cancer |
WO2005082901A1 (en) * | 2004-02-25 | 2005-09-09 | Smithkline Beecham Corporation | Novel chemical compounds |
-
2007
- 2007-04-25 RU RU2008146422/04A patent/RU2008146422A/en not_active Application Discontinuation
- 2007-04-25 EP EP07755981A patent/EP2016062A2/en not_active Withdrawn
- 2007-04-25 MX MX2008013668A patent/MX2008013668A/en not_active Application Discontinuation
- 2007-04-25 KR KR1020087028782A patent/KR20090007609A/en not_active Application Discontinuation
- 2007-04-25 AU AU2007243403A patent/AU2007243403A1/en not_active Abandoned
- 2007-04-25 JP JP2009507765A patent/JP2009536622A/en not_active Withdrawn
- 2007-04-25 CN CNA2007800208258A patent/CN101460471A/en active Pending
- 2007-04-25 CA CA002650028A patent/CA2650028A1/en not_active Abandoned
- 2007-04-25 WO PCT/US2007/009959 patent/WO2007127212A2/en active Application Filing
-
2008
- 2008-10-23 IL IL194890A patent/IL194890A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047760A2 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Novel chemical compounds |
US20050038051A1 (en) * | 2003-06-09 | 2005-02-17 | Jodi Nunnari | Novel molecules for regulating cell death |
US20050042213A1 (en) * | 2003-08-14 | 2005-02-24 | Insight Biopharmaceuticals Ltd. | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
WO2005051318A2 (en) * | 2003-11-24 | 2005-06-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
WO2005082363A1 (en) * | 2004-02-20 | 2005-09-09 | Board Of Regents, The University Of Texas System | Thiazolone compounds for treatment of cancer |
WO2005082901A1 (en) * | 2004-02-25 | 2005-09-09 | Smithkline Beecham Corporation | Novel chemical compounds |
Non-Patent Citations (2)
Title |
---|
TOLEDO-SHERMAN LETICIA ET AL: "Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening.", JOURNAL OF MEDICINAL CHEMISTRY 5 MAY 2005, vol. 48, no. 9, 5 May 2005 (2005-05-05), pages 3221 - 3230, XP002448944, ISSN: 0022-2623 * |
TONGHUI MA ET AL: "High-Affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 40, 4 October 2002 (2002-10-04), pages 37235 - 37241, XP002327308, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
RU2008146422A (en) | 2010-05-27 |
CA2650028A1 (en) | 2007-11-08 |
CN101460471A (en) | 2009-06-17 |
MX2008013668A (en) | 2009-01-27 |
KR20090007609A (en) | 2009-01-19 |
WO2007127212A2 (en) | 2007-11-08 |
JP2009536622A (en) | 2009-10-15 |
AU2007243403A1 (en) | 2007-11-08 |
EP2016062A2 (en) | 2009-01-21 |
IL194890A0 (en) | 2009-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007127212A3 (en) | Anti-viral agents that activate rnase l | |
WO2008052187A3 (en) | Antibodies and immunoconjugates and uses therefor | |
WO2007146259A3 (en) | Composite assembly and methods of making and using the same | |
CA119671S (en) | Television receiver | |
WO2007130697A3 (en) | Anti-ephb4 antibodies and methods using same | |
WO2008046104A3 (en) | Methods and systems for knowledge discovery | |
EP2021370A4 (en) | Trail receptor-binding agents and uses of the same | |
EP1759973B8 (en) | Running object and method of controlling the same | |
WO2007075987A3 (en) | Active surface coupled polymerases | |
WO2007140371A8 (en) | Antibodies and immunoconjugates and uses therefor | |
WO2005097825A3 (en) | Bmp-7 variants with improved properties | |
WO2008085570A3 (en) | Flux formulations | |
IL211889A (en) | Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof as nadph oxidase inhibitors | |
WO2006050341A3 (en) | Modified streptococcal polysaccharides and uses thereof | |
EP1943875A4 (en) | Headset and method of using the same | |
WO2007016702A3 (en) | Chimeric polymerases | |
GB0616111D0 (en) | Agents, methods and uses | |
WO2008060795A3 (en) | Antimicrobial articles and method of manufacture | |
WO2008027600A3 (en) | Imatinib compositions | |
WO2007127506A3 (en) | Anti-ephrinb2 antibodies and methods using same | |
WO2007149932A3 (en) | Methods and compositions for targeting hepsin | |
WO2010057143A8 (en) | Water-soluble multi-layer materials, articles made therefrom and methods of making and using the same | |
WO2011050188A8 (en) | Anti-hepsin antibodies and methods using same | |
CA117351S (en) | Iron | |
WO2006089166A3 (en) | Food serving arrangement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780020825.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07755981 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2650028 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 194890 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009507765 Country of ref document: JP Ref document number: MX/A/2008/013668 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007243403 Country of ref document: AU Ref document number: 9558/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007755981 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008146422 Country of ref document: RU Ref document number: 1020087028782 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2007243403 Country of ref document: AU Date of ref document: 20070425 Kind code of ref document: A |